135 related articles for article (PubMed ID: 12065874)
1. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.
Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564
[TBL] [Abstract][Full Text] [Related]
3. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Heino J; Pyrhönen S
Melanoma Res; 2004 Feb; 14(1):29-37. PubMed ID: 15091191
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Franssila K; Collan Y; Pyrhönen S
Oncology; 1999 Oct; 57(3):242-52. PubMed ID: 10545794
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of beta1 integrin expression in metastatic melanoma.
Vihinen P; Nikkola J; Vlaykova T; Hahka-Kemppinen M; Talve L; Heino J; Pyrhönen S
Melanoma Res; 2000 Jun; 10(3):243-51. PubMed ID: 10890378
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of biomarkers in malignant melanoma.
Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
[TBL] [Abstract][Full Text] [Related]
7. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
[TBL] [Abstract][Full Text] [Related]
9. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
Sparrow LE; English DR; Taran JM; Heenan PJ
Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.
Tchernev G; Orfanos CE
J Cutan Pathol; 2007 Mar; 34(3):247-56. PubMed ID: 17302609
[TBL] [Abstract][Full Text] [Related]
14. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
17. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Flørenes VA; Maelandsmo GM; Kerbel RS; Slingerland JM; Nesland JM; Holm R
Am J Pathol; 1998 Jul; 153(1):305-12. PubMed ID: 9665492
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
19. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer.
Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Czyzewska J
Anticancer Res; 2009 Aug; 29(8):3049-52. PubMed ID: 19661314
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
